OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might ...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company ...

Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects ...

BEDFORD, Mass. — BEDFORD, Mass. — Ocular Therapeutix Inc. (OCUL) on Tuesday reported a loss of $64.8 million in its first quarter. On a per-share basis, the Bedford, Massachusetts-based company said ...

Ocular Therapeutix will be reporting Q1 earnings on May 7. Analysts on Wall Street predict Ocular Therapeutix will release losses per share of $0.193. Go here to follow Ocular Therapeutix stock price ...

AHF has launched a new national public awareness campaign using the image of two giant bloodshot, infected eyes and the ...

Friends, family, and supporters got together on Sunday, May 5 at Central Standard Distillery for the Milwaukee Walk for ...

Colloquially known as moon blindness, equine recurrent uveitis (ERU) is an inflammatory ocular disease in horses, which can ...

A study in the Journal of Clinical Medicine reveals that exposure to e-cigarette vapor can lead to both accidental and direct ...

Warning! GuruFocus has detected 3 Warning Signs with OCUL. Ocular Therapeutix Inc (NASDAQ:OCUL) released its 8-K filing on ...